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Abstract
Background: In a cluster randomised controlled trial (CRCT), randomisation units are “clusters” such as schools or
GP practices. This has methodological implications for study design and statistical analysis, since clustering often
leads to correlation between observations which, if not accounted for, can lead to spurious conclusions of efficacy/
effectiveness. Bayesian methodology offers a flexible, intuitive framework to deal with such issues, but its use within
CRCT design and analysis appears limited. This review aims to explore and quantify the use of Bayesian
methodology in the design and analysis of CRCTs, and appraise the quality of reporting against CONSORT
guidelines.
Methods: We sought to identify all reported/published CRCTs that incorporated Bayesian methodology and papers
reporting development of new Bayesian methodology in this context, without restriction on publication date or
location. We searched Medline and Embase and the Cochrane Central Register of Controlled Trials (CENTRAL).
Reporting quality metrics according to the CONSORT extension for CRCTs were collected, as well as demographic
data, type and nature of Bayesian methodology used, journal endorsement of CONSORT guidelines, and statistician
involvement.
Results: Twenty-seven publications were included, six from an additional hand search. Eleven (40.7%) were reports
of CRCT results: seven (25.9%) were primary results papers and four (14.8%) reported secondary results. Thirteen
papers (48.1%) reported Bayesian methodological developments, the remaining three (11.1%) compared different
methods. Four (57.1%) of the primary results papers described the method of sample size calculation; none clearly
accounted for clustering. Six (85.7%) clearly accounted for clustering in the analysis. All results papers reported use
of Bayesian methods in the analysis but none in the design or sample size calculation.
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Conclusions: The popularity of the CRCT design has increased rapidly in the last twenty years but this has not
been mirrored by an uptake of Bayesian methodology in this context. Of studies using Bayesian methodology,
there were some differences in reporting quality compared to CRCTs in general, but this study provided insufficient
data to draw firm conclusions. There is an opportunity to further develop Bayesian methodology for the design and
analysis of CRCTs in order to expand the accessibility, availability, and, ultimately, use of this approach.
Keywords: Cluster randomised trial, Bayesian, CONSORT statement, Sample size, Statistical power, Hierarchical
modelling
Background
In a cluster randomised controlled trial (CRCT), ran-
domisation occurs at the group (or “cluster”) level as op-
posed to the individual level that is typical in traditional
Randomised Controlled Trials (RCTs). Examples of
naturally-occurring clusters include schools, villages and
GP practices. Randomisation of clusters, rather than in-
dividuals, is conducted for a number of reasons: (i) when
the intervention is to be delivered at the cluster level
(e.g. to a whole school/class within a school); (ii) when
there is a risk of contamination, either between partici-
pants or those delivering the intervention; or (iii) when
there is a clear administrative, logistic or cost-based ra-
tionale [1].
Cluster randomisation has methodological implica-
tions that go beyond merely the randomisation proced-
ure itself. Measurements on individuals within the same
cluster are likely to be more correlated to one another
than measurements on individuals from different clus-
ters. This correlation creates an additional level of com-
plexity, which must be accounted for in both the study
design and sample size calculation, and the statistical
analysis. Failure to do so can result in an underpowered
study and ultimately spurious conclusions about the effi-
cacy or effectiveness of the intervention or treatment
under investigation.
CRCTs are a relatively novel study design, but the
methodology is now well established in the literature.
Prior to the 1980s, there was only sparse use of CRCTs
[2], but they have become increasingly popular in the
last 30 years, from just seven reported in 1990, to over
120 in 2008 [3, 4]. Figure 1 provides an illustration of
this increase in popularity by displaying the number of
search results by year for “cluster randomised controlled
trials” with restriction to publication title. Alongside
such a rapid increase in the use of the CRCT design,
there have been some attempts to develop new Bayesian
methodology for the design and analysis of such trials.
This ranges from utilising well-established Bayesian hier-
archical modelling approaches to account for the clus-
tered nature of the data [5], through to more novel
approaches to study design and sample size calculation
such as that developed by Turner et al [6, 7]. The
Bayesian approach to analysis in particular may offer a
number of advantages over the frequentist approach. In
a random effects setting, as is often applicable in the
analysis of a CRCT, the hierarchical Bayesian framework
provides a flexible, intuitive approach to statistical infer-
ence. Furthermore, Bayesian analysis facilitates a more
natural, probabilistic interpretation of results and moves
away from frequentist hypothesis testing and p-values,
an approach which has been criticised in recent years
[8]. Whilst often criticised, the incorporation of prior in-
formation into a statistical analysis can facilitate more
informative conclusions, which reflect all the available
evidence as opposed to simply the evidence offered from
the single dataset at hand. In many cases, the rationale
for the inclusion of informative priors is sound, for ex-
ample results from previous research or even existing
data (such as pilot or feasibility studies). However, whilst
the advantages of the Bayesian approach to both the
analysis of clinical trials [9] and hierarchical data [10]
are clear and have been documented, it is unclear
whether such methods are being regularly utilised within
the context of CRCTs.
With the increased use of CRCTs, the need for con-
sistent, high-quality reporting is crucial. In response to
this recognised need, the CONSORT extension to clus-
ter randomised trials was first published in 2004 [11]
and updated in 2012 [12]. The CONSORT statement
provides recommendations for reporting of randomised
trials, and whilst there is no extension for Bayesian trials,
it was not written exclusively for frequentist methods. A
recent review of the methodological quality of sample
size calculations in a sample of 300 CRCTs published
between 2000 and 2008, found that only 55.3% (166)
presented a sample size calculation, of which only 61.4%
(102) accounted appropriately for clustering [13]. A sep-
arate recently published review of the same sample of
CRCTs examined the impact of the 2004 CONSORT ex-
tension on more general methodological quality and
concluded that adherence to published reporting guide-
lines and quality remains low [14]. Similar reviews of
CRCT reporting quality have been conducted and pro-
duced comparable conclusions [15, 16]. However, to our
knowledge, none have focussed specifically on CRCTs
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which incorporated Bayesian methods, and so both the
quantity and quality of these are unknown.
This review aims to:
(i) Quantify and explore the use of Bayesian method-
ology in the design and/or analysis of CRCTs;
(ii) Appraise the quality of reporting of CRCTs con-
ducted in a Bayesian framework against the current rele-
vant CONSORT guidelines and identify whether the
reporting quality differs from previous reviews assessing
reporting quality in CRCTs more generally (most of
which likely, but not necessarily, pertain to frequentist
trials).
The impact of the introduction of the CONSORT
guidelines for CRCTs in 2004 and 2012 on reporting
quality will also be appraised.
Methods
The protocol for this methodological systematic review
was developed prospectively and made publically avail-
able online [17] before commencing the literature
searches. The review was conducted and reported in ac-
cordance with the PRISMA guidelines [18].
Inclusion and exclusion criteria
We sought to identify all published parallel group
CRCTs in which Bayesian methodology was used in ei-
ther the study design (including sample size calculation)
or statistical analysis. We also opted to include any pa-
pers in which Bayesian methodology was discussed or
considered, even if such methods were not implemented
in the study, whilst recognising that such a scenario
would be unlikely. We did not restrict our search or in-
clusion on the basis of publication date, location, inter-
vention type or population in any way, provided the
relevant paper was published in the English language,
due to resource limitations.
In order to be included in this review, it had to be evi-
dent that randomisation in the study occurred at a group
level, in which multiple participants were randomised
together, as per the definition of a CRCT.
Fig. 1 Number of PubMed search results per year. Search term: “cluster randomized controlled trial”[Title] OR “cluster randomised controlled
trial”[Title] NOT “stepped”[Title]. The search was conducted in February 2019 and partial data for that year was removed
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We did not exclude references on the basis of type
(category) of published paper. Specifically, we included
not only primary reports of efficacy or effectiveness but
also protocol papers, papers reporting secondary ana-
lyses and publications reporting results of pilot/feasibility
studies. We also included studies reporting Bayesian
methodological developments in the area of CRCTs. At
the data extraction stage, we sought to identify supple-
mentary literature related to the same study, if indicated,
to obtain the required information, but only included
such examples as a single entry. It was anticipated, for
example, that this might include obtaining additional de-
tail from a published protocol or monograph that had
been omitted in the corresponding primary results
paper.
We excluded papers reporting only cost-effectiveness.
We also excluded studies implementing a stepped-
wedge or other longitudinal cluster randomised design,
as the methodological considerations are different and
the reporting quality metrics presented in the CON-
SORT extension to CRCTs [12] are not valid for such
longitudinal designs. Since commencement of this sys-
tematic review, however, separate guidelines for stepped-
wedge designs have been published [19]. Conference
proceedings and masters and PhD dissertations were not
included.
Data sources and search methods
We searched both Medline and Embase using Ovid, as
well as the Cochrane Central Register of Controlled Tri-
als (CENTRAL), for relevant publications on 24 July
2018, without restriction on date of publication. The full
electronic search strategy was an extension of that pre-
sented by Taljaard et al. [20] to identify CRCTs, adapted
to identify only studies including the word “Bayes” in the
title, abstract or text. The full electronic search strategy
used to search Medline and Embase is shown in Table 1,
with minor syntactic adaptations required in order to
run the search in CENTRAL. The searches were under-
taken by BJ. Additional literature was included where
appropriate through hand searching of the authors’ own
collection of references.
Reference sifting and quality control
After conducting electronic searches, all references were
downloaded and imported to Mendeley [21] for elec-
tronic deduplication. Following this, remaining refer-
ences were exported and uploaded to Rayyan [22]. BJ
and AS independently reviewed each reference and
made a decision to include or exclude on the basis of
the information available from the title and the abstract
assessed against the pre-specified inclusion/exclusion
criteria outlined in the protocol [17]. Rayyan includes a
blinding feature, which was switched on during the
independent sifts and then disabled. Any disagreements
were resolved through discussion and, where required,
SC made a final decision.
After the initial sift, full-text articles were obtained for
all remaining references. BJ examined the full texts and
again made inclusion/exclusion decisions using Rayyan.
SC or AB re-examined approximately half each of all full
texts and independently made inclusion or exclusion de-
cisions. Any disagreements were once again resolved
through further discussion.
Data extraction
For the primary and secondary published reports of trial
results, we collected a range of data including demo-
graphic data, technical detail regarding design and ana-
lysis methodology with relation to Bayesian techniques,
and information regarding statistician involvement with
the study and their respective affiliations. For papers
reporting primary results, we also collected a selection
Table 1 Search strategy used to search Medline and Embase
within Ovid on 24 July 2018
# Search
Existing published strategy for randomised controlled trials
1 (article OR randomized controlled trials).pt.
2 Animals/
3 Humans/
4 #2 NOT (2 AND 3)
5 #1 NOT #4
Cluster design–related terms
6 (cluster$ adj2 randomi$).tw.
7 ((communit$ adj2 intervention$) or (communit$ adj2 randomi$)).tw.
8 group$ randomi$.tw.






15 #10 OR #11 OR #12 OR #13 OR #14
16 #9 OR #15
Bayesian search terms
17 bayes$.af.
18 #16 AND #17
Final search
19 #18 AND #5
20 limit #19 to (randomized controlled trial)
pt. represents publication type; / represents MeSH search; $ allows for
truncation of words; adj allows for adjacency between search words; tw
represents text words in abstract and/or title; af represents all fields; ? is a
wildcard which retrieves one or 0 characters
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of reporting quality metrics taken from the 2012 CON-
SORT extension to CRCTs [12]. In addition, we re-
corded whether or not p-values were reported for
comparison of baseline demographics, as has been col-
lected in previous systematic reviews of CRCTs [15, 23],
Clinical Trial Unit (CTU) involvement in the study, and
journal endorsement of the CONSORT guidelines.
We considered the paper as having statistician in-
volvement, via a previously used criterion [15, 24, 25],
if there was a clearly designated statistician, or if at
least one of the co-authors belonged to a department
of epidemiology or biostatistics. If it was not possible
to obtain this information from the authorship list on
the paper, online searching was undertaken to at-
tempt to determine this from the qualification or af-
filiation of the authors. In any cases where it was not
possible to obtain the required information, statisti-
cian involvement was recorded as “no”. We also re-
corded the statistician’s affiliation to a CTU, an
academic statistical department, a commercial
pharmaceutical company, a clinical research organisa-
tion (CRO) or “other”. CTU involvement in the study
was determined if at least one author had a listed af-
filiation to a CTU. If author affiliations were not
available in the paper or online, this was recorded as
“no”.
We classified journal endorsement of the CON-
SORT statement using previously defined criteria
[15]: a journal’s strength of endorsement was classi-
fied as high if the words “required”, ”must”, ”should”
or “strongly recommended” were used in their au-
thor instructions, a medium endorser if words “en-
couraged”, ”recommended”, “advised” or “please”
were used, and a low endorser if “may wish to con-
sider” or ”see CONSORT” was used. We included a
fourth category, “none”, if the journal included no
mention of the CONSORT statement in its guide-
lines to authors.
Separate data extraction forms were developed for
primary and secondary results papers to ensure that
all the required information was obtained independ-
ently, consistently and without bias. The forms were
piloted by BJ prior to data extraction. Formal data ex-
traction was not undertaken for the methodological
papers, but rather these papers were examined for the
purpose of qualitative reporting and descriptive sum-
maries of the methods developed in order to gain an
understanding of the extent of methodological devel-
opments in this area.
BJ conducted data extraction on all primary and sec-
ondary results papers. SC, AB and AS independently
conducted approximately one-third each of the data ex-
traction on all papers, and final data was agreed by the
whole study team. BJ and SC also each independently
classified the results papers as primary or secondary.
Any disagreements were resolved through discussion.
Separately, BJ examined the methodological papers for
qualitative reporting, but no second data extraction was
undertaken. BJ double-entered all data from the data ex-
traction forms into separate excel spreadsheets for pri-
mary and secondary papers.
Analysis
We present descriptive statistics of frequencies and per-
centages or means and standard deviations, as appropri-
ate, for demographic qualities relating to each of the
results publications, including trial location, number of
participants recruited and type of primary outcome, by
category of published results (primary or secondary). For
the reporting quality measures, we present the number
of primary results papers satisfying each criterion overall,
by year (before or after the publication of the 2012 ex-
tension to the CONSORT guidelines for CRCTs [12]),
by journal endorsement of the CONSORT guidelines
(high or medium versus low or none) and by statistician
involvement in the trial. We also summarise the use or
consideration of Bayesian methods in the design and/or
sample size calculation and/or analysis, as well as the
level of information incorporated into the prior distribu-
tions specified. We also outline for which parameters
the prior distributions were specified, if this information
was available. Finally, a qualitative synthesis of the meth-
odological papers was undertaken to summarise the
areas of focus in the development of new methods.
Results
We identified 325 records from our electronic searches,
of which 48 were identified as duplicates and removed.
The remaining 277 records were screened on the basis
of the detail available within the title and abstract, of
which 219 were excluded (51 were the wrong study de-
sign (such as N-of-1 trials or meta analyses), 160 were
individually randomised trials, and eight were papers
reporting cost-effectiveness only). Full texts were ob-
tained for the remaining 58 papers. At this final stage,
following independent review of the full texts, a further
37 were removed (25 were individually randomised, five
did not include any mention of Bayesian methodology,
six were the wrong study design and one paper reported
only cost-effectiveness results), leaving 21 papers from
the electronic search. A further six papers, all of which
were methodological, were added through additional
hand searches, resulting in a total of 27 papers included
(Fig. 2). The full list of references for the included papers
is detailed in Table 2. Eleven (40.7%) were reports of
CRCT results, of which seven (63.6%, R1–R7) were pri-
mary results papers and four (36.4%, R8–R11) reported
secondary analyses. Thirteen papers (48.1%, M1–M13)
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reported methodological developments and the
remaining three (11.1%, C1–C3) reported comparisons
of methods, assessing the performance of various exist-
ing methodology.
Demographics
Descriptions of demographics are displayed in Table
3. Target sample sizes and numbers of clusters were
only collected for primary results papers. We
deemed it necessary to distinguish “numbers
approached” from target sample sizes, as the num-
bers approached seemed likely driven by logistical
rather than statistical considerations, and so were
not included in the summary statistics of the target
sample sizes. Clear statistician association with a
CTU was identified in one (12.5%) study. We were
unable to identify more general CTU involvement
with trial or data management in any instance.
Reporting quality
Reporting quality of the seven primary results papers
was mixed (Table 4). Four (57.1%) included a descrip-
tion of the sample size calculation, but none of these
clearly accounted for clustering, provided the intra-
class correlation coefficient (ICC) used in the sample
size calculation or took into consideration potential
variability in cluster size or accounted for this in the
sample size calculation. Similarly, none of the papers
reported estimated ICCs for any of the primary or
secondary outcomes, despite the potential value of
Fig. 2 Flow diagram of the identification process for the 27 publications included in this review
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such estimates in informing the design of future stud-
ies. However, it was clear in six (85.7%) of the pri-
mary results papers how clustering was accounted for
in the statistical analysis.
Reporting quality metrics have also been summarised
by the following: (i) publication date before or after the
publication of the CONSORT extension to CRCTs in
2012 [12]; (ii) journal endorsement of the CONSORT
Table 2 References included in the review
R1 Carabin H, Millogo A, Ngowi HA, et al. Effectiveness of a community-based educational programme in reducing the cumulative incidence and prevalence of human
Taenia solium cysticercosis in Burkina Faso in 2011–14 (EFECAB): a cluster-randomised controlled trial. Lancet Glob Heal. 2018;6(4):e411-e425. doi:10.1016/S2214-
109X(18)30027-5
R2 Foxcroft DR, Callen H, Davies EL, Okulicz-Kozaryn K. Effectiveness of the strengthening families programme 10-14 in Poland: Cluster randomized controlled trial. Eur
J Public Health. 2017;27(3):494-500. doi:10.1093/eurpub/ckw195
R3 Levy BT, Hartz A, Woodworth G, Xu Y, Sinift S. Interventions to Improving Osteoporosis Screening: An Iowa Research Network (IRENE) Study. J Am Board Fam Med.
2009;22(4):360-367. doi:10.3122/jabfm.2009.04.080071
R4 Ngowi HA, Carabin H, Kassuku AA, Mlozi MRS, Mlangwa JED, Willingham AL. A health-education intervention trial to reduce porcine cysticercosis in Mbulu District,
Tanzania. Prev Vet Med. 2008;85(1-2):52-67. doi:10.1016/j.prevetmed.2007.12.014
R5 Rahme E, Choquette D, Beaulieu M, et al. Impact of a general practitioner educational intervention on osteoarthritis treatment in an elderly population. Am J Med.
2005;118(11):1262-1270. doi:10.1016/j.amjmed.2005.03.026
R6 Swanson KM, Chen H-T, Graham JC, Wojnar DM, Petras A. Resolution of Depression and Grief during the First Year after Miscarriage: A Randomized Controlled Clin-
ical Trial of Couples-Focused Interventions. J Women’s Heal. 2009;18(8):1245-1257. doi:10.1089/jwh.2008.1202
R7 Van Deurssen E, Meijster T, Oude Hengel KM, et al. Effectiveness of a Multidimensional Randomized Control Intervention to Reduce Quartz Exposure among
Construction Workers. Ann Occup Hyg. 2015;59(8):959-971. doi:10.1093/annhyg/mev037
R8 Amza A, Kadri B, Nassirou B, et al. Community risk factors for ocular chlamydia infection in Niger: Pre-treatment results from a cluster-randomized trachoma trial.
PLoS Negl Trop Dis. 2012;6(4). doi:10.1371/journal.pntd.0001586
R9 Hovi T, Ollgren J, Savolainen-Kopra C, T. H, J. O. Intensified hand-hygiene campaign including soap-and-water wash may prevent acute infections in office workers,
as shown by a recognized-exposure -adjusted analysis of a randomized trial. BMC Infect Dis. 2017;17(1):47. doi:https://doi.org/10.1186/s12879-016-2157-z
R10 Barlis P, Regar E, Serruys PW, et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: A LEADERS trial sub-
study. Eur Heart J. 2010;31(2):165-176. doi:10.1093/eurheartj/ehp480
R11 See CW, O’Brien KS, Keenan JD, et al. The effect of mass azithromycin distribution on childhood mortality: Beliefs and estimates of efficacy. Am J Trop Med Hyg.
2015;93(5):1106-1109. doi:10.1111/sjos.12316
M1 Alexander N, Emerson P. Analysis of incidence rates in cluster-randomized trials of interventions against recurrent infections, with an application to trachoma. Stat
Med. 2005;24(17):2637-2647. doi:10.1002/sim.2138
M2 Clark AB, Bachmann MO. Bayesian methods of analysis for cluster randomized trials with count outcome data. Stat Med. 2010;29(2):199-209. doi:10.1002/sim.3747
M3 Nixon RM, Duffy SW, Fender GR. Imputation of a true endpoint from a surrogate: Application to a cluster randomized controlled trial with partial information on
the true endpoint. BMC Med Res Methodol. 2003;3:1-11. doi:10.1186/1471-2288-3-17
M4 Olsen MK, DeLong ER, Oddone EZ, Bosworth HB. Strategies for analyzing multilevel cluster-randomized studies with binary outcomes collected at varying intervals
of time. Stat Med. 2008;27(29):6055-6071. doi:10.1002/sim.3446
M5 Thompson SG, Warn DE, Turner RM. Bayesian methods for analysis of binary outcome data in cluster randomized trials on the absolute risk scale. Stat Med. 2004;
23(3):389-410. doi:10.1002/sim.1567
M6 Turner RM, Prevost AT, Thompson SG. Allowing for imprecision of the intracluster correlation coefficient in the design of cluster randomized trials. Stat Med. 2004;
23(8):1195-1214. doi:10.1002/sim.1721
M7 Turner RM, Omar RZ, Thompson SG. Modelling multivariate outcomes in hierarchical data, with application to cluster randomised trials. Biometrical J. 2006;48(3):333-
345. doi:10.1002/bimj.200310147
M8 Spiegelhalter DJ. Bayesian methods for cluster randomized trials with continuous responses. Stat Med. 2001;20(3):435-452. doi:10.1002/1097-0258(20010215)20:3<
435::AID-SIM804>3.0.CO;2-E
M9 Kikuchi T, Gittins J. A behavioural Bayes approach for sample size determination in cluster randomized clinical trials. J R Stat Soc Ser C Appl Stat. 2010;59(5):875-888.
doi:10.1111/j.1467-9876.2010.00732.x
M10 Turner RM, Thompson SG, Spiegelhalter DJ. Prior distributions for the intracluster correlation coefficient, based on multiple previous estimates, and their application
in cluster randomized trials. Clin Trials. 2005;2(2):108-118. doi:10.1191/1740774505cn072oa
M11 Turner RM, Omar RZ, Thompson SG. Constructing intervals for the intracluster correlation coefficient using Bayesian modelling, and application in cluster
randomized trials. Stat Med. 2006;25(9):1443-1456. doi:10.1002/sim.2304
M12 Uhlmann L, Jensen K, Kieser M. Bayesian network meta-analysis for cluster randomized trials with binary outcomes. Res Synth Methods. 2016;8(October 2015):236-
250. doi:10.1002/jrsm.1210
M13 Turner RM, Omar RZ, Thompson SG. Bayesian methods of analysis for cluster randomized trials with binary outcome data. Stat Med. 2001;20(3):453-472. doi:10.1002/
1097-0258(20010215)20:3<453::AID-SIM803>3.0.CO;2-L
C1 Peters TJ, Richards SH, Bankhead CR, Ades AE, Sterne JAC. Comparison of methods for analysing cluster randomized trials: An example involving a factorial design.
Int J Epidemiol. 2003;32(5):840-846. doi:10.1093/ije/dyg228
C2 Pacheco GD, Hattendorf J, Colford JM, Mäusezahl D, Smith T. Performance of analytical methods for overdispersed counts in cluster randomized trials: Sample size,
degree of clustering and imbalance. Stat Med. 2009;28(24):2989-3011. doi:10.1002/sim.3681
C3 Ma J, Thabane L, Kaczorowski J, et al. Comparison of Bayesian and classical methods in the analysis of cluster randomized controlled trials with a binary outcome:
The community hypertension assessment trial (CHAT). BMC Med Res Methodol. 2009;9(1). doi:10.1186/1471-2288-9-37
Prefix “R” refers to results papers, “M” to methodological papers and “C” to comparison of methods papers
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guidelines [12]; and (iii) involvement of a statistician in
the study (Table 4). Due to the small number of avail-
able papers, we dichotomised journal endorsement of
the CONSORT guidelines into “High” or “Medium” ver-
sus “Low” or “None”. We intended to summarise these
results by three time periods (pre-2005, 2005–2012 and
2012–2018) to assess any effect of the publication of the
CONSORT extensions for CRCTs in 2004 and 2012 on
reporting quality. However, we were unable to identify
any CRCTs using Bayesian methodology published be-
fore 2005. Pre-specified quality metrics are detailed in
Table 4. However, due to the small number of primary
results papers identified (seven in total), no meaningful
comparisons can be made.
One of the papers retrieved was a pre-specified sub-
study and so was classified as a secondary results paper
(Table 2, R10). We noted that reporting quality, despite
not being a primary results paper and therefore not obli-
gated to follow CONSORT guidelines, was high: a sam-
ple size calculation was presented and appropriately
accounted for clustering, including specification of the
assumed ICC; the flow of clusters and individuals
through the study was well documented; and all levels of
clustering were accounted for within a hierarchical mod-
elling framework.
Use of Bayesian methodology
We were unable to identify any results papers in which a
Bayesian approach was taken, or even discussed, for
study design or sample size calculation. One secondary
paper did, however, specify that the design factor used
to inflate the sample size calculation was derived from
the results of a Bayesian hierarchical model.
Of the eleven results papers included in the review, all
adopted some form of Bayesian approach to statistical
analysis (Table 5). In nine (81.8%; R1–R7, R9, R10) of
the 11 papers, hierarchical modelling techniques were
employed to account for the clustered structure of the
data. Another study employed Bayes Model Averaging
(R8) in order to mitigate the risks of overfitting that can
be associated with stepwise regression in model-fitting.
One study conducted a literature search of Cochrane Re-
views and extracted the key summary statistic (mortality)
before converting each into a log-odds ratio. These sta-
tistics were combined into a single arithmetic mean in
order to construct an empirical prior. This prior was
then combined with the likelihood from the CRCT to
obtain a Bayesian posterior distribution of the relative
risk of mortality in the intervention group versus the
control group (R11).
In these results papers, prior distributions were in-
formative in two (18.2%; R3, R11) papers; in one, (R3)
“collateral” information from a previous study was used
to construct a prior distribution for the variation in
practice effects (specifically, the standard deviation for
practice-level rates); in the other (R11) an informative
prior distribution for the treatment effect parameter
within a negative binomial regression was constructed
based on a meta-analysis of relevant reviews obtained
from the Cochrane library, and used to inform the esti-
mation of the outcome of interest (the relative risk of
childhood mortality). No information was provided on
the prior distributions placed on the variance compo-
nents. Weakly informative prior distributions were used
in one (9.1%; R2) study, by placing Student’s t priors
centred at 0 on the treatment effect parameter and other
fixed logistic regression coefficients, which the authors
acknowledged would only affect inference if the data
provide little information about the parameters. No de-
tail was provided on the prior distributions specified for
the variance components in this paper. Five (45.5%; R1,
R3, R5, R9, R10) papers specified the use of non-
informative prior distributions, although only one of
these (R5) provided more specific detail, stating normal
prior distributions for the treatment effect and each of
the fixed logistic regression coefficients, and uniform
prior distributions for the variance components. Four
studies (36.4%; R4, R6, R7, R8) did not specify their
choice of prior distribution. One paper fitted two Bayes-
ian models (R3) - one model implementing a non-
informative prior and the other utilising “collateral” in-
formation, so we recorded the use of both an inform-
ative and a non-informative prior.
Bayesian methodological developments
We categorised 13 (48.1%) of the 27 papers included as
methodological papers, where the focus was on the de-
velopment of Bayesian methods for use in the design or
analysis of CRCTs, as opposed to applying existing
methods to data from CRCTs. Of these 13 papers, we
defined 11 (84.6%) as “pure” methods papers, in which
Bayesian methodological developments are reported in-
dependently of an applied scenario (although study data
may have been used to demonstrate the method). We
categorised two (15.4%) papers as being methodological
but with the developments being driven by a specific
statistical problem encountered in a CRCT, in which the
method is presented and subsequently used to analyse
the data of interest. Finally, we categorised three (11.1%)
of the 27 papers as comparison of methods papers, in
which existing methodology (both Bayesian and frequen-
tist) were applied to the same data for comparative
purposes.
Of the 11 “pure” methodological papers, seven pre-
sented analysis methods (63.6%; M2, M4, M5, M7, M11,
M12, M13), two presented methods for design/sample
size calculation (18.2%; M6, M9) and two presented ele-
ments of both (18.2%; M8, M10). Both papers driven by
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Table 3 Demographic data for the eleven results papers
N (%) unless otherwise stated Total (N = 11) Primary (N = 7) Secondary (N = 4)
Year of publication
Pre 2005 0 (0.0) 0 (0.0) 0 (0.0)
2005–2012 6 (54.5) 4 (57.1) 2 (50.0)
Post 2012 5 (45.5) 3 (42.9) 2 (50.0)
Location of first authora
UK 2 (18.2) 1 (14.3) 1 (25.0)
US/Canada 5 (45.5) 4 (57.1) 1 (25.0)
Europe excl. UK 3 (27.3) 1 (14.3) 2 (50.0)
Australia/New Zealand 0 (0.0) 0 (0.0) 0 (0.0)
Africa 2 (18.2) 1 (14.3) 1 (25.0)
Asia 0 (0.0) 0 (0.0) 0 (0.0)
Other 0 (0.0) 0 (0.0) 0 (0.0)
Location of studya
UK 1 (9.1) 0 (0.0) 1 (25.0)
US/Canada 3 (27.3) 3 (42.9) 0 (0.0)
Europe excl. UK 4 (36.4) 2 (28.6) 2 (50.0)
Australia/New Zealand 0 (0.0) 0 (0.0) 0 (0.0)
Africa 4 (36.4) 2 (28.6) 2 (50.0)
Asia 0 (0.0) 0 (0.0) 0 (0.0)
Other 0 (0.0) 0 (0.0) 0 (0.0)



























Medical facility 1 (9.1) 1 (14.3) 0 (0.0)
Village/community/district 6 (54.5) 4 (57.1) 2 (50.0)
Organisation 1 (9.1) 1 (14.3) 0 (0.0)
Couple 1 (9.1) 1 (14.3) 0 (0.0)
Individual 1 (9.1) 0 (0.0) 1 (25.0)
Working unit (office) 1 (9.1) 0 (0.0) 1 (25.0)
Primary outcome type
Binary 9 (81.8) 5 (71.4) 4 (100.0)
Continuous 2 (18.2) 2 (28.6) 0 (0.0)
Statistician involvement 8 (72.7) 5 (71.4) 3 (75.0)
Statistician association
Clinical trials unit 1 (12.5) 0 (0.0) 1 (33.3)
Academic statistical department 7 (87.5) 5 (100.0) 2 (66.6)
Commercial pharmaceutical company 0 (0.0) 0 (0.0) 0 (0.0)
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specific application presented analysis methods (M1,
M3).
The analysis methods papers predominantly presented
hierarchical modelling methodology applied to dealing
with a range of data types, such as incidence rates (M1),
count data (M2) and binary data (M4, M5,M13), in a
Bayesian setting, citing flexibility of modelling and the
ability to incorporate prior information and account for
the complex variance structures as key advantages. One
paper reports Bayesian methods for modelling multivari-
ate outcomes (M7), which allow for multiple outcomes
without concern for multiplicity whilst accommodating
complex correlation structures. Another paper presents
Bayesian network meta-analysis methods for CRCTs
(M12), allowing for comparison of multiple treatment
arms whilst accounting for the complex correlation
structure inherent in clustered data.
A number of methodological papers identified within
our review focus on the ICC. One such paper centres on
analysis only, presenting methods for constructing inter-
vals for the ICC and suggesting prior distributions for
use in modelling (M11). The two papers in which both
design and analysis are discussed focus heavily on the
ICC; one provides a range of options for choice of prior
distribution alongside recommendations, before discuss-
ing briefly how the uncertainty in the ICC can be
accounted for in sample size calculations (M8). The
other paper presents methods for formulating prior dis-
tributions for use in sample size calculations and statis-
tical analysis on the basis of multiple previous estimates,
whilst incorporating the relevance of the studies from
which they were obtained (M10). One of the papers pre-
senting only study design methodology also focused on
ICCs, and developed methods to formulate prior distri-
butions from single and multiple previous ICC estimates
for use in sample size calculations (M6).
The remaining study design paper presented a behav-
ioural Bayes approach (M9), extending existing method-
ology [26–29] for sample size determination in
individually randomised trials to CRCTs. The method
incorporates estimated financial costs and benefits of the
intervention to produce a net benefit, rather than being
based on the more usual difference in primary outcome
alone.
Discussion
To the best of our knowledge, this is the first methodo-
logical systematic review of the use, or consideration of,
Bayesian methods in CRCTs.
As the number of included papers is small, drawing
robust conclusions regarding overall reporting quality
between subgroups (Table 4) is not possible. However,
in 2013, Diaz-Ordaz presented a summary of reviews of
CRCT quality, in which the percentage of studies ac-
counting for clustering in the sample size calculation
and statistical analysis ranged from 0% to 71% and 37%
to 92%, respectively [15]. We have identified an add-
itional review of reporting and methodological quality of
CRCTs published in 2016 [16]. Including the data from
the more recent review together with Diaz-Ordaz’s sum-
mary, the mean (SD) percentage of studies accounting
for clustering in the sample size calculation and analysis
was 34.6 (23.7) and 64.2 (16.3), respectively. For com-
parison, our study identified no papers which clearly
accounted for clustering in the sample size calculation,
and six (85.7%) papers accounting for clustering in the
analysis. Although our review included only a small
number of papers, reporting quality according to these
key metrics may differ somewhat between studies using
Bayesian methodology and the wider pool of CRCTs, as
none of the papers we identified clearly accounted for
clustering in sample size calculation. Hence, there is a
need to further improve the reporting of CRCTs utilising
Bayesian methodology. Conversely, Bayesian CRCTs
seem to more often account for clustering in analysis.
This is likely due to the popularity of Bayesian hierarch-
ical modelling within the set of included papers, which is
a natural way to conduct mixed or random effects mod-
elling and therefore inherently account for clustering.
Table 3 Demographic data for the eleven results papers (Continued)
N (%) unless otherwise stated Total (N = 11) Primary (N = 7) Secondary (N = 4)
Clinical research organisation 0 (0.0) 0 (0.0) 0 (0.0)
Other 0 (0.0) 0 (0.0) 0 (0.0)
Journal endorsement of CONSORT guidelines
High N/A 3 (42.9) N/A
Medium N/A 1 (14.3) N/A
Low N/A 0 (0.0) N/A
None N/A 3 (42.9) N/A
aOne author was associated with an institution in both Europe and the UK, and the associated study was run across both locations. The denominator used for the
calculations is based on the number of papers
bTwo studies specified the number of participants approached but these were not explicitly stated/justified recruitment targets and so were excluded
cFour studies specified the number of clusters approached but these were not explicitly stated/justified recruitment targets and so were excluded
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Table 4 Reporting quality metrics for seven primary results papers
Reporting quality criteria N (%) Total
(N =
7)
















Description of sample size method 4
(57.1)
2 (50.0) 2 (66.7) 2 (50.0) 2 (66.7) 2 (40.0) 2
(100.0)
Was clustering clearly accounted for in sample
size calculation
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Specification of the required number of clusters 2
(50.0)
1 (50.0) 1 (50.0) 1 (50.0) 1 (50.0) 1 (50.0) 1 (50.0)
Specification of the assumed cluster size 2
(50.0)
1 (50.0) 1 (50.0) 1 (50.0) 1 (50.0) 1 (50.0) 1 (50.0)
Specification of whether equal or unequal
cluster sizes are assumed
1
(25.0)
1 (50.0) 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0) 1 (50.0)
Variability in cluster size accounted for 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Specification of the ICC used for the sample
size
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Indication of the uncertainty of the ICC N/A N/A N/A N/A N/A N/A N/A
Accounted for the uncertainty in the ICC N/A N/A N/A N/A N/A N/A N/A
Other CONSORT metrics




4 (100.0) 2 (66.7) 4 (100.0) 2 (66.7) 5 (100.0) 1 (50.0)




4 (100.0) 3 (100.0) 4 (100.0) 3 (100.0) 5 (100.0) 2
(100.0)
Specification of the number of clusters receiving intended treatment
Explicit 5
(71.4)
3 (75.0) 2 (66.7) 4 (100.0) 1 (33.3) 4 (80.0) 1 (50.0)
Implied 2
(28.6)
1 (25.0) 1 (33.3) 0 (0.0) 2 (66.7) 1 (20.0) 1 (50.0)
Specification of the number of clusters analysed for the primary outcome at the primary endpoint
Explicit 2
(28.6)
1 (25.0) 1 (33.3) 2 (50.0) 0 (0.0) 2 (40.0) 0 (0.0)
Implied 5
(71.4)
3 (75.0) 2 (66.7) 2 (50.0) 3 (100.0) 3 (60.0) 2
(100.0)
Details of cluster-level losses and exclusions
Explicit 3
(42.9)
2 (50.0) 1 (33.3) 2 (50.0) 1 (33.3) 2 (40.0) 1 (50.0)
Implied 4
(57.1)
2 (50.0) 2 (66.7) 2 (50.0) 2 (66.7) 3 (60.0) 1 (50.0)
Details of individual-level losses and exclusions 4
(57.1)






4 (100.0) 3 (100.0) 4 (100.0) 3 (100.0) 5 (100.0) 2
(100.0)
Cluster-level baseline characteristics presented 2
(28.6)
2 (50.0) 0 (0.0) 1 (25.0) 1 (33.3) 1 (20.0) 1 (50.0)
Coefficients of intracluster correlation provided for primary outcomes
All 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Some 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Coefficients of intracluster correlation provided for secondary outcomes
All 0
(0.0)a
0 (0.0) 0 (0.0)a 0 (0.0) 0 (0.0)a 0 (0.0) 0 (0.0)a
Some 0
(0.0)a
0 (0.0) 0 (0.0)a 0 (0.0) 0 (0.0)a 0 (0.0) 0 (0.0)a
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Evidently, the use of Bayesian methods in the design
or analysis of CRCTs remains uncommon relative to the
use of frequentist methods (Fig. 1), with only eleven pri-
mary or secondary results papers reporting doing so.
This is despite the increasing use of CRCT designs, with
over 120 reported in 2008 alone [4] and the number of
PubMed search results rising almost year-on-year since
2006 (Fig. 1) reaching 347 in 2018. This methodological
systematic review failed to identify a single reported
CRCT which utilised a Bayesian approach to conduct
the sample size calculation, despite some efforts to de-
velop methodology in this area, as highlighted in the
methodological aspect of our review. Whilst explaining
the reason for this lack of uptake of Bayesian method-
ology in the design of CRCTs would be little more than
speculation, possibilities include fundamental disagree-
ments with the approach, still limited development of
methodology, inaccessibility of software to implement
the methods or lack of knowledge or understanding.
Whilst we have shown that there has been some Bayes-
ian methodological developments in both design and
analysis of CRCTs, these have been limited in compari-
son to the development of classical methods which are
now well-established in the literature. None of the
thirteen published methodological papers appears to
have developed publicly available software in order to
aid implementation (although some papers reported that
code is available from the authors on request), whereas
classical analysis and sample size calculations for CRCTs
can be conducted with relative ease in standard statis-
tical software. As such, there is need to increase the
availability and accessibility of these methods, which can
offer advantages over the frequentist approach within
the CRCT context.
A common criticism of the Bayesian approach in gen-
eral, and in particular within the analysis of clinical trial
data, is the subjective nature of the choice of prior distri-
bution, although it is strongly recommended that sensi-
tivity analyses be performed in order to assess the
strength of the effect of the prior [30]. Interestingly,
however, only two (18.2%) of the 11 results papers that
were identified utilised an informative prior distribution,
and one (9.1%) utilised a weakly informative prior. Five
(45.5%) specified an uninformative prior (of which one
employed two models). It is likely that the four (36.4%)
papers that did not report their choice of prior used an
uncontroversial, uninformative formulation, and in
doing so, a likely total of nine (81.8%) studies
Table 4 Reporting quality metrics for seven primary results papers (Continued)
Reporting quality criteria N (%) Total
(N =
7)
















P-values provided for baseline comparisons 5
(71.4)
3 (75.0) 2 (66.7) 3 (75.0) 2 (66.7) 3 (60.0) 2
(100.0)
Clustering accounted for in the calculation of the p-values
Yes 1
(20.0)
1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0)
Unclear 1
(20.0)
1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0)
aOne study did not have any secondary outcomes
Table 5 Summary of Bayesian Methods used in primary and secondary results papers
N (%) Total (N = 11) Primary (N = 7) Secondary (N = 4)
Sample Size (used) 0 (0.0) 0 (0.0) 0 (0.0)
Sample Size (discussed) 0 (0.0) 0 (0.0) 0 (0.0)
Analysis (used) 11 (100.0) 7 (100.0) 4 (100.0)
Priors used
Informative 2 (18.2)a 1 (14.3)a 1 (25.0)
Weakly Informative 1 (9.1) 1 (14.3) 0 (0.0)
Non-informative 5 (45.5)a 3 (42.9)a 2 (50.0)
Unspecified 4 (36.4) 3 (42.9) 1 (25.0)
Analysis (discussed) N/A N/A N/A
aOne paper reported the use of two Bayesian models — the first model implementing a non-informative prior and the second model utilising
“collateral” information
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circumvented the perceived issues surrounding the
choice of an informative prior. Despite this, the use of a
well-justified, informative prior distribution has the po-
tential to add value to a statistical analysis, and meth-
odological development for informative yet rigorous
prior specification for CRCTs may enhance the uptake
of Bayesian methods in this area.
Strengths and limitations
A protocol for this methodological systematic review
was published before commencement of the electronic
search [17] and the review was conducted according to
the PRISMA guidelines [18]. The electronic search strat-
egy to identify Bayesian approaches in CRCTs was
adapted from a previously published strategy, which was
demonstrated to have high precision [20] in identifying
CRCTs. In this study, each stage of the reference sifting
and data extraction process was fully conducted twice,
independently, to ensure accurate inclusion of references
and high-quality data for examination. We developed
data extraction forms for primary and secondary results
papers in order to aid in the accurate and consistent col-
lection of data. Furthermore, the final data extraction
was agreed by all four members of the study team.
The reporting quality metrics collected are predomin-
antly a subset of the CONSORT checklist for CRCTs, a
well-accepted set of criteria. We added a small number
of additional items such as whether cluster size variabil-
ity had been accounted for in the presented sample size
calculation [4] and whether p-values for baseline com-
parisons were provided, in order to facilitate a robust
judgement of reporting quality.
Despite this, we acknowledge the possibility that we
may have missed some publications in which Bayesian
methodology was used or considered in the design or
analysis of CRCTs. In particular, we opted for a search
strategy in which specificity was maximised, rather than
sensitivity, in order to make the sifting process more
manageable with limited resource. We added six add-
itional methodological papers through hand searching,
but were unable to identify any additional trial results
papers. This is not surprising given the search strategy
was developed to identify the latter, but may suggest a
greater risk that further methodological papers have
been missed compared to trial results papers.
Furthermore, we present reporting quality metrics by
journal endorsement of the CONSORT guidelines. How-
ever, we acknowledge that the guidelines may, in some
cases, have changed since the date of the associated pub-
lications, and as a result, a journal’s endorsement may
have been intensified since the included papers were ac-
cepted for publication. To the best of our knowledge,
this issue has not been raised in previous systematic re-
views of trial reporting quality; archiving of journal
guidelines would help researchers conducting quality as-
sessment systematic reviews in the future. Similarly, we
sought to identify author affiliations during data collec-
tion, but again acknowledge that these may have chan-
ged since publication of the research, particularly for
papers published some time ago.
We intended to summarise the pre-specified reporting
quality metrics by time periods (pre-2005, 2005–2012
and 2012–2018) according to publication date to assess
the effect of the relevant CONSORT statements on
reporting quality. We acknowledge that the time delay
between completion of the study and submission of the
final report for publication may have resulted in some
studies being categorised as published after the publica-
tion of the CONSORT extension guidance, when in fact
it was designed, conducted and possibly even analysed
before.
Conclusion
The use of Bayesian methods in the statistical analysis of
CRCTs is rare and was not found at all in the design of
any of the reviewed studies or their sample size calcula-
tions. There have been some developments in Bayesian
methodology for CRCTs but far less so than within the
frequentist paradigm. Reporting quality may differ be-
tween CRCTs utilising Bayesian methodology compared
with previous reviews of CRCT quality, although the
number of papers identified in this review is small.
There is a need for further Bayesian methodological de-
velopments in the design and analysis of CRCTs, includ-
ing approaches for the specification of prior
distributions, as well as statistical software development
to allow easier implementation of methods, in order to
increase the accessibility, availability and, ultimately, use
of the approach.
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